Remix Therapeutics Granted FDA Fast Track Designation for REM-422 for the Treatment of Recurrent, Metastatic or ...
Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA Degrader No Approved Treatment Options for Patients with MYB-Driven Solid Tumor Adenoid Cystic Carcinoma WATERTOWN, …